Swipe Left For English News
1
公司在全球185个国家的逾15万家参评企业中排名前1%
2
坚守可持续发展承诺的举措深受全球客户信赖
3
引领绿色生物药发展，技术创新赋能健康未来
上海,
2025年2月18日
全球领先的合同研究、开发和生产（CRDMO）服务公司药明生物（WuXi Biologics, 2269.HK）宣布，公司获得国际权威企业可持续发展评估机构EcoVadis授予的最高殊荣“铂金”评级。药明生物凭借在可持续发展领域的杰出成绩，连续两年获此认可。
EcoVadis是全球供应链领域领先的可持续发展评级机构，其评级从环境、劳工与人权、商业道德和可持续采购四大主题进行评估，下设21项可持续发展标准与7项管理指标，全面衡量企业的可持续发展表现。EcoVadis通过系统评估企业的政策制定、实施举措及成果输出，并综合第三方专家及外部利益相关方的专业意见，形成权威评级结果。在最新发布的评级榜单中，药明生物从全球逾15万家参评企业中脱颖而出，位列前1%。
陈智胜
博士
药明生物首席执行官
ESG委员会主席
我们非常荣幸再度荣膺EcoVadis‘铂金’评级，这不仅是对我们可持续发展能力的高度认可，更是对我们长期践行ESG理念的充分肯定。作为全球绿色生物药解决方案领域的引领者，我们始终致力于以卓越的ESG实践赋能全球合作伙伴，推动其迈向ESG发展新高度。未来，我们将持续携手各方，共同推动整个价值链的负责任发展，为全球生物制药行业的绿色转型贡献力量。
作为联合国全球契约组织（UNGC）和制药供应链倡议组织（PSCI）成员，药明生物积极倡导可持续发展的战略举措并赢得业界广泛认可。凭借领先的绿色生物药解决方案（Green CRDMO），公司成功入选UNGC “‘二十年二十佳’企业可持续发展案例”报告；连续两年获得明晟（MSCI）最高AAA ESG评级、入选道琼斯可持续发展指数（DJSI）；连续五年获评晨星Sustainalytics ESG“行业最高评级”及“区域最高评级”；跻身CDP水安全“A级榜单”并获得CDP气候变化领导力级别评分A-；入选富时社会责任指数系列；入选恒生ESG 50指数，充分彰显了公司在可持续发展领域的卓越表现。
关于药明生物
药明生物（股票代码：2269.HK）是一家全球领先的合同研究、开发和生产（CRDMO）公司。公司通过开放式、一体化生物制药能力和技术赋能平台，提供全方位的端到端服务，帮助合作伙伴发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。
药明生物在中国、美国、爱尔兰、德国和新加坡拥有超过12000名员工。通过药明生物的专业服务团队，以及先进技术和精深洞见，公司为客户提供高效经济的生物药解决方案。截至2024年12月底，药明生物帮助客户研发和生产的综合项目高达817个，其中包括21个商业化生产项目（不包括新冠项目）。
药明生物将环境、社会和治理（ESG）视为业务发展和企业精神的重要组成部分，并致力于成为全球生物药CRDMO领域的ESG领导者，例如应用更绿色环保的新一代生物制药技术和能源等引领行业发展。公司成立了由首席执行官领导的ESG委员会，全面落实ESG战略并践行可持续性发展承诺。更多信息，请访问：www.wuxibiologics.com。
ESG
esg@wuxibiologics.com
媒体关系
PR@wuxibiologics.com
WuXi Biologics Awarded Platinum Medal by EcoVadis Sustainability Rating for Second Consecutive Year
1
Ranked among the top 1% of more than 150,000 companies across 185 countries
2
Trusted by global partners for strong sustainability commitment
3
Recognized as a leader in Green CRDMO, driving innovation for a healthier future
Shanghai,
February 18, 2025
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been awarded a Platinum Medal by the EcoVadis Sustainability Rating, marking the second year the company has received the rating's highest level of recognition.
EcoVadis is a leading sustainability intelligence platform for global supply chains. Its sustainability ratings cover seven management indicators, across 21 sustainability criteria, under four main themes: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement. The performance of companies is evaluated by assessing their policies, actions and results, and weighing inputs that come from third-party professionals and external stakeholders. In the newly published ratings scorecard, WuXi Biologics was ranked in the top 1% of more than 150,000 companies evaluated worldwide.
Dr. Chris Chen
Chief Executive Officer
Chairman of the ESG Committee
WuXi Biologics
We are very pleased to be once again recognized by EcoVadis with the Platinum Medal, which reflects our success in enhancing our sustainability capabilities. As a global leader in Green CRDMO, we are committed to continuously delivering ESG excellence, enabling partners worldwide to fulfill ESG goals, and jointly working with all stakeholders to promote responsible practices throughout the entire value chain.
As a participant in the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI), WuXi Biologics proactively contributes to advocating sustainability, and has earned widespread recognition for its efforts. It was included in the UNGC 20 Case Examples of Sustainable Development for 20 Years Collection for its world-leading green biologics solutions; granted an MSCI AAA Rating and included in Dow Jones Sustainability Indices for two consecutive years; recognized as a Sustainalytics industry and regional ESG top-rated company for five consecutive years; named to the CDP Water Security "A list" and awarded an "A-" CDP Climate Change score; selected as a Constituent of the FTSE4Good Index Series; and listed in the Hang Seng ESG 50 Index.
About
WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2024, WuXi Biologics is supporting 817 integrated client projects, including 21 in commercial manufacturing (excluding COVID CMO projects).
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to be an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com
Contacts
ESG
esg@wuxibiologics.com
Media
PR@wuxibiologics.com
注：本信息不构成药明生物的信息披露或投资建议
